Selleck Chemicals is your Trusted Supplier
for Inhibitors, Antibodies, Proteins, Kits and Reagents

Selleck products have been cited in studies from Nature, Science and Cell.

17 Nobel Prize winners have published 60 papers with Selleck products.
The Nobel Prize

Shimon Sakaguchi

Nobel Prize in Physiology or Medicine 2025

David Baker

Nobel Prize in Chemistry in 2024

Katalin Karikó

Nobel Prize in Physiology or Medicine in 2023

David Julius

Nobel Prize in Physiology or Medicine in 2021

Michael Houghton

Nobel Prize in Physiology or Medicine in 2020

Charles M. Rice

Nobel Prize in Physiology or Medicine in 2020

William G. Kaelin Jr

Nobel Prize in Physiology or Medicine in 2019

Peter J. Ratcliffe

Nobel Prize in Physiology or Medicine in 2019

Gregg L. Semenza

Nobel Prize in Physiology or Medicine in 2019

James P. Allison

Nobel Prize in Physiology or Medicine in 2018

Michael Rosbash

Nobel Prize in Physiology or Medicine in 2017

Shinya Yamanaka

Nobel Prize in Physiology or Medicine in 2012

Eric Richard Kandel

Nobel Prize in Physiology or Medicine in 2000

Aziz Sancar

Nobel Prize in Chemistry in 2015

Brian K. Kobilka

Nobel Prize in Chemistry in 2012

Robert Lefkowitz

Nobel Prize in Chemistry in 2012

Aaron Ciechanover

Nobel Prize in Chemistry in 2004

Signaling Pathway Inhibitors
PD-1/PD-L1 Inhibitors ROCK Inhibitors Ras Inhibitors TGF-beta/Smad Inhibitors Immunology & Inflammation related Inhibitors CDK Inhibitors DNA/RNA Synthesis Inhibitors Antineoplastic and Immunosuppressive Antibiotics GSK-3 Inhibitors CD markers Inhibitors Ferroptosis Inhibitors & Activators EGFR Inhibitors JAK Inhibitors VEGFR Inhibitors PARP Inhibitors HDAC Inhibitors PI3K Inhibitors Bcl-2 Inhibitors Caspase Inhibitors & Activators Proteasome Inhibitors ATM/ATR Inhibitors Glucagon Receptor Inhibitors HER2 Inhibitors Hydrotropic Agents Inhibitors ADC Inhibitors mTOR Inhibitors Raf Inhibitors Histone Methyltransferase Inhibitors MEK Inhibitors Interleukins Inhibitors Epigenetic Reader Domain Inhibitors Akt Inhibitors Dehydrogenase Inhibitors Wnt/beta-catenin Inhibitors Androgen Receptor Inhibitors STING Inhibitors Estrogen/progestogen Receptor Inhibitors Antibody-Drug Conjugate CSF-1R Inhibitors EZH2 Inhibitors Microtubule Associated Inhibitors STAT Inhibitors Secretase Inhibitors PKA Inhibitors DNA-PK Inhibitors PKC Inhibitors Topoisomerase Inhibitors gp120/CD4 Inhibitors NF-κB Inhibitors AMPK Inhibitors MLL Inhibitors
New Products

JNJ-9350

JNJ-9350 is a chemical probe that inhibits spermine oxidase (SMOX) with an IC50 of 0.01 μM. This compound also shows inhibitory activity against polyamine oxidase (PAO), exhibiting an IC50 of 0.79 μM. JNJ-9350 has potential applications in cancer research.

VQW-765

VQW-765 (AQW-051) is an orally active agonist targeting the alpha-7 nicotinic acetylcholine receptor (α7-nAChR), exhibiting a pKD of 7.56 for the human recombinant α7-nAChR. This compound demonstrates anxiolytic-like activity in animal models. VQW-765 has potential applications in anxiety disorder and acute performance anxiety studies.

Asundexian

Asundexian (BAY 2433334) is an orally administered inhibitor of coagulation factor XIa (FXIa). It binds reversibly to the FXIa active site with high affinity, blocking its enzymatic function. In buffer systems, asundexian exhibits an IC50 of 1 nM against human FXIa.

STAT3-IN-13

STAT3-IN-13 (compound 6f) is a STAT3 inhibitor. It exhibits anti-proliferative activity and binds to the STAT3 SH2 domain with a KD of 0.46 μM. This compound inhibits STAT3 Y705 phosphorylation and downstream target gene expression. In vitro studies show STAT3-IN-13 induces apoptosis, while in vivo experiments demonstrate its ability to suppress tumor growth and metastasis. STAT3-IN-13 has potential applications in cancer research.

BBO-10203

BBO-10203 inhibits PI3Kα and KRASG12C by covalently binding to Cys242 in the PI3Kα RAS-Binding Domain. It inhibits both GTP-bound and GDP-bound KRASG12C states, with IC50 and EC50 values of 0.031 nM and 0.02 nM respectively. This compound interferes with RAS-PI3Kα interaction, suppressing RAS-dependent PI3Kα activation. It decreases pERK levels, inhibits cell proliferation, and causes G1 phase arrest and apoptosis. BBO-10203 has potential applications in breast cancer, colorectal cancer, and non-small cell lung cancer research.

GE11

GE11 is an active peptide that binds with colloidal drug delivery systems, serving as smart carriers for antitumor drugs in cancer research.

DPhPC

DPhPC is a phosphatidylcholine (PC) derivative employed in the synthesis of bilayer vesicle phospholipids. The DPhPC bilayer membranes exhibit minimal ion leakage in the absence of pores or ion channels, making them suitable for investigating ion channel activity and membrane potential regulation. DPhPC-based nanoliposomes (NTG) enhance nitric oxide (NO) bioavailability and demonstrate anti-inflammatory properties.

CHOP Antibody [C21N8]

CHOP,DDIT3,DDIT3/GADD153/CHOP,GADD153/CHOP

HSL Antibody [M23F5]

Hormone sensitive lipase/HSL,HSL

CA9 Antibody [J19A24]

CA9,Carbonic Anhydrase 9/CA9,Carbonic Anhydrase IX/CA9

Sp7/Osterix Antibody [J12J9]

OSX,Sp7 / Osterix

CD11b + CD11c Antibody [C8C21]

CD11b + CD11c,CD11b/c

VSV-G tag Antibody [N12B16]

VSV Glycoprotein,VSV-G tag

α-adaptin A Antibody [D21J17]

alpha Adaptin,alpha-Adaptin,α-Adaptin 1/2

Phospho-SHP2 (Tyr542) Antibody [J17K6]

Phospho-SHP-2 (Tyr542),SHP2 (phospho Y542)

Phospho-STAT1 (Ser727) Antibody [F23C16]

Phospho-Stat1 (Ser727),STAT1 (phospho S727)

Influenza A Virus M2 Protein Antibody [L21L24]

Influenza A M2,Influenza A Virus M2 Protein

IFN-γ Antibody [A4P20]

IFN-γ,Interferon gamma

TIM-3 Antibody [N19P14]

TIM 3,TIM-3

ZO1 tight junction protein Antibody [A24G22]

Tight Junction Protein 1,ZO-1,ZO1 tight junction protein
Click to View More